Heartflow (NASDAQ:HTFL – Get Free Report) had its price target hoisted by investment analysts at Wells Fargo & Company from $39.00 to $70.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 44.45% from the stock’s current price.
Several other analysts have also issued reports on HTFL. Piper Sandler reaffirmed an “overweight” rating and set a $64.00 price target (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. JPMorgan Chase & Co. lifted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Heartflow in a research note on Wednesday, November 4th. Stifel Nicolaus boosted their price objective on shares of Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. Finally, UBS Group began coverage on shares of Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and an average price target of $60.12.
Get Our Latest Research Report on HTFL
Heartflow Trading Down 19.1%
Shares of NASDAQ:HTFL traded down $11.46 during trading on Friday, hitting $48.46. 3,705,135 shares of the company were exchanged, compared to its average volume of 1,763,967. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $60.65. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of -52.67 and a beta of 2.50. The firm has a fifty day moving average price of $51.91 and a two-hundred day moving average price of $35.23.
Heartflow (NASDAQ:HTFL – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 20.42% and a negative net margin of 33.11%. The company had revenue of $72.86 million during the quarter. During the same period in the previous year, the company posted ($0.27) EPS. As a group, research analysts predict that Heartflow will post -0.75 EPS for the current year.
Insider Buying and Selling
In related news, CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the transaction, the chief financial officer directly owned 184,789 shares of the company’s stock, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $49.57, for a total value of $1,928,273.00. Following the completion of the sale, the chief executive officer owned 283,014 shares in the company, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 332,403 shares of company stock valued at $16,602,786. 7.70% of the stock is owned by insiders.
Institutional Trading of Heartflow
A number of hedge funds have recently modified their holdings of HTFL. GAMMA Investing LLC grew its stake in Heartflow by 75.1% in the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after buying an additional 275 shares during the last quarter. IFP Advisors Inc lifted its position in Heartflow by 844.7% during the third quarter. IFP Advisors Inc now owns 803 shares of the company’s stock worth $40,000 after acquiring an additional 718 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Heartflow by 116.4% during the third quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after acquiring an additional 616 shares during the period. Integrated Wealth Concepts LLC bought a new stake in shares of Heartflow during the second quarter worth approximately $53,000. Finally, Essential Partners LLC acquired a new position in shares of Heartflow in the first quarter valued at approximately $57,000.
More Heartflow News
Here’s some of the latest news about HTFL:
- Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.5 million consensus, signaling stronger expected growth. Financial results and guidance
- Positive Sentiment: Wells Fargo, Canaccord Genuity, Stifel and Baird raised their price targets to $68–$70 and maintained positive ratings, reflecting improved analyst expectations. Wells Fargo rating Canaccord Genuity rating Stifel rating Baird rating
- Negative Sentiment: A report said Heartflow’s CEO sold about $2.17 million worth of stock. Insider selling can concern investors, though the report alone does not establish the reason for the sale. CEO stock sale
About Heartflow
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
See Also
- Five stocks we like better than Heartflow
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
